ERBB2 and cancer: Data from the National Cancer Data Base (NCDB) (29), a hospital-based but much larger U.S national cancer registry that covers approximately 70% of all newly diagnosed cancer cases in the country (41), included 260,174 breast cancer patients and consistently revealed that Latinas and AAs are more likely to develop luminal/HER2 tumors (Latinas: OR=1.11, 95% CI, 1.04-1.17; AAs: OR=1.13, 95% CI, 1.08–1.18) and the HER2-enriched subtype (Latinas: OR=1.26; 95% CI 1.16–1.37; AAs: OR=1.17, 95% CI, 1.10–1.25), compared to NHWs.